1. Additional data on ARRY-520 + carfilzomib combo will be presented at EHA (believe in a few weeks) but sounds like the really mature data will be presented at ASH in December.
2. More buzz for the Phase 2 selumetinib uveal melanoma data that is an oral presentation at ASCO. Data will be unveiled at the presentation. Squarer implied the data would be good and said there could be a fast path to market for selumetinib here. (The other oral presentation is for selumetinib+DTIC in BRAF melanoma; I saw the abstract and while PFS looked very good for selumetinib+DTIC, the OS benefit seemed to be minimal.)
3. Another ASCO presentation (poster) is for MEK162 plus NVS' BRAF inhibitor in BRAF melanoma. Squarer alluded to the safety advantages of the combo relative to competition.
4. Reference to an MDS patient that has been on ARRY-614 for 3 years now and now has a "practical cure." Patient had failed both Vidaza and Dacogen, which is patient population ARRY is pursuing with 614.